Publications
September 13, 2024
Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors
April 10, 2024
Identification of Debio 0432 as a potent and selective USP1 Inhibitor for Cancer Therapy